MX9300904A - Composiciones que contienen acido hialuronico - Google Patents

Composiciones que contienen acido hialuronico

Info

Publication number
MX9300904A
MX9300904A MX9300904A MX9300904A MX9300904A MX 9300904 A MX9300904 A MX 9300904A MX 9300904 A MX9300904 A MX 9300904A MX 9300904 A MX9300904 A MX 9300904A MX 9300904 A MX9300904 A MX 9300904A
Authority
MX
Mexico
Prior art keywords
skin
tissue
exposed
hyaluronic acid
transport
Prior art date
Application number
MX9300904A
Other languages
English (en)
Inventor
Rudolf Edgar Falk
Samuel Simon Asculai
Ehud Shmuel Klein
David William Harper
David Hochman
Don Purschke
Original Assignee
Norpharmco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norpharmco Inc filed Critical Norpharmco Inc
Publication of MX9300904A publication Critical patent/MX9300904A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Composiciones farmacéuticas a partir de las cuales pueden tomarse y aplicarse de cantidades de dosis no tóxicas (para el paciente) efectivas a la piel y/o tejido expuesto de un paciente humano, cada cantidad de dosis efectiva comprende excipientes farmacéuticos adecuados para la aplicación tópica, una cantidad de dosis no tóxica efectiva de una droga para tratar y para ayudar a resolver una enfermedad y/o condición de la piel y/o tejido expuesto de un paciente humano y una cantidad de dosis no tóxica efectiva de ácido hialurónico y/o sales del mismo y/u homólogos, análogos, derivados, complejos, ésteres, fragmentos y/o sub-unidades del ácido hialurónico suficiente para transportar (facilitar u ocasionar el transporte de) la droga hacia un sitio en la piel que incluye la epidermis o tejido expuesto de una enfermedad o condición, para el transporte percutáneo al interior de la piel y/o tejido expuesto a fin de acumularse y permanecer ahí por un periodo prolongado de tiempo, y que actúa en forma sistémico-independiente.
MX9300904A 1992-02-20 1993-02-19 Composiciones que contienen acido hialuronico MX9300904A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002061703A CA2061703C (en) 1992-02-20 1992-02-20 Formulations containing hyaluronic acid

Publications (1)

Publication Number Publication Date
MX9300904A true MX9300904A (es) 1993-10-01

Family

ID=4149316

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9300904A MX9300904A (es) 1992-02-20 1993-02-19 Composiciones que contienen acido hialuronico

Country Status (28)

Country Link
US (1) US6140312A (es)
EP (1) EP0626863B1 (es)
JP (1) JPH07506812A (es)
KR (1) KR100315371B1 (es)
CN (1) CN1103219C (es)
AP (1) AP475A (es)
AT (1) ATE200736T1 (es)
AU (1) AU3488893A (es)
CA (1) CA2061703C (es)
CZ (1) CZ290637B6 (es)
DE (1) DE69330180T2 (es)
DK (1) DK0626863T3 (es)
ES (1) ES2156124T3 (es)
FI (1) FI113522B (es)
GR (1) GR3036164T3 (es)
HK (1) HK1005983A1 (es)
HU (2) HU225967B1 (es)
IN (5) IN175918B (es)
MD (1) MD960307A (es)
MX (1) MX9300904A (es)
NO (1) NO312939B1 (es)
NZ (2) NZ299280A (es)
PL (1) PL173211B1 (es)
PT (1) PT626863E (es)
RO (1) RO117499B1 (es)
SG (1) SG52416A1 (es)
SK (1) SK11193A3 (es)
WO (1) WO1993016732A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006622A1 (en) * 1991-07-03 1996-03-07 Hyal Pharmaceutical Corporation Hyaluronic acid and derivatives for modulation of cellular activity
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
CA2130762C (en) * 1994-08-24 1999-07-06 Eva Anne Turley Treatment of disease and conditions associated with macrophage infiltration
EP0774970A4 (en) * 1994-08-10 2000-02-02 Roderick T Coward METHOD FOR USING HYALURONIC ACID FOR DETECTING, LOCALIZING AND DIAGNOSING TUMORS
JP4010574B2 (ja) * 1994-12-05 2007-11-21 電気化学工業株式会社 皮膚外用剤
US5626838A (en) * 1995-03-13 1997-05-06 The Procter & Gamble Company Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx
CA2154103C (en) * 1995-07-18 1998-02-24 Samuel Simon Asculai Treatment of mucous membrane disease, trauma or condition and for the relief of pain
US6875753B1 (en) 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
US5939047A (en) * 1996-04-16 1999-08-17 Jernberg; Gary R. Local delivery of chemotherapeutic agents for treatment of periodontal disease
EP0963196B1 (en) 1996-09-27 2005-01-19 Jagotec Ag Hyaluronic drug delivery system
DE69828193T2 (de) * 1997-10-31 2005-12-01 The Board Of Regents Of The University Of Oklahoma, Norman Hyaluronan synthase gen und seine verwendung
ATE501275T1 (de) * 1998-04-02 2011-03-15 Univ Oklahoma State Chondroitin-synthase kodierendes dna der pasteurella multocida und verwendungsverfahren
WO2000038647A1 (de) * 1998-12-23 2000-07-06 Esparma Gmbh Mittel zum schutz der haut, enthaltend ein aus hyaluronsäure durch hydrolyse hergestelltes fragmentgemisch
ES2295005T3 (es) 1999-01-13 2008-04-16 Alchemia Oncology Pty Limited Uso de hialuronano para la preparacion de un medicamento para la mejora de la eficacia de farmacos citotoxicos.
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US6828308B2 (en) * 2000-07-28 2004-12-07 Sinclair Pharmaceuticals, Ltd. Compositions and methods for the treatment or prevention of inflammation
US6726898B2 (en) 2000-11-17 2004-04-27 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US6576226B1 (en) 2000-11-17 2003-06-10 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
ES2607802T3 (es) * 2001-08-14 2017-04-04 Tel Aviv University Future Technology Development L.P. Partículas lipidadas de glicosaminoglicano y su uso en el suministro de fármacos y genes para diagnóstico y terapia
US20030143165A1 (en) * 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
US7622117B2 (en) 2002-04-17 2009-11-24 Dynamis Therapeutics, Inc. 3-deoxyglucosone and skin
KR100518152B1 (ko) 2002-05-09 2005-09-29 메디제네스(주) 혈장 또는 혈청을 함유한 창상 치료용 약학 조성물
US8088605B2 (en) * 2002-12-04 2012-01-03 Technologies Biolactics Inc. Exopolysaccharides delivery system for active molecules
CN101921347B (zh) * 2004-01-07 2014-07-30 生化学工业株式会社 透明质酸衍生物及含有其的药剂
FR2865651B1 (fr) * 2004-01-29 2007-09-28 Fabre Pierre Dermo Cosmetique Compositions topiques associant des fragments de hyaluronate de sodium et un retinoide utiles en dermatologie cosmetique et medicale
US20050266064A1 (en) * 2004-05-29 2005-12-01 Mccarthy Kathryn J Cosmetic compositions and methods
EP1912658B1 (en) 2005-07-27 2017-01-25 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
US7323184B2 (en) 2005-08-22 2008-01-29 Healagenics, Inc. Compositions and methods for the treatment of wounds and the reduction of scar formation
AU2006289651B2 (en) 2005-09-07 2012-07-26 Alchemia Oncology Pty Limited Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
JP2009528382A (ja) * 2006-03-01 2009-08-06 トリストラータ・インコーポレイテッド タール応答性皮膚疾患の局所治療のための組成物及び方法
NZ575334A (en) 2006-09-13 2012-03-30 Enhance Skin Products Inc Cosmetic composition for the treatment of skin and methods thereof
WO2008073295A2 (en) * 2006-12-07 2008-06-19 Surmodics, Inc. Latent stabilization of bioactive agents releasable from implantable medical articles
ITMI20071267A1 (it) * 2007-06-22 2008-12-23 Fidia Farmaceutici Uso di coniugati dell'acido ialuronico nel trattamento locale di malattie cutanee iperproliferative
GB0913442D0 (en) 2009-07-31 2009-09-16 Univ Ramot Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
ITMI20110644A1 (it) * 2011-04-14 2012-10-15 Giuliani Spa Sistema per il rilascio prolungato di agenti cosmetici
IN2014MN01886A (es) 2012-04-18 2015-07-10 Univ Ramot
FR2994846B1 (fr) 2012-08-29 2014-12-26 Vivacy Lab Composition, sterilisee, comprenant au moins un acide hyaluronique et de l'ascorbyl phosphate de magnesium
KR101439032B1 (ko) * 2013-06-13 2014-09-05 동아에스티 주식회사 피록시캄과 히알루론산을 포함하는 골관절염 치료를 위한 액상 조성물
WO2015198326A1 (en) 2014-06-26 2015-12-30 Ramot At Tel-Aviv University Ltd. Liposomal formulations for delivery of nucleic acids
UY36404A (es) 2014-11-21 2016-06-01 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware ANTICUERPOS MONOCLONALES (Ab) COMO DETECTORES DE CD73 E INHIBIDORES DE SU ACTIVIDAD ENZIMÁTICA, Y COMPOSICIONES QUE LOS CONTIENEN
CA2995552C (en) * 2015-09-04 2023-08-01 Elena POLI Composition and medical device comprising acetylsalicylic acid for the treatment of human papilloma virus skin infections
CN109965104A (zh) * 2019-03-29 2019-07-05 华熙生物科技股份有限公司 一种含透明质酸钠的组合物及其制备方法和应用
KR20230122164A (ko) * 2020-02-25 2023-08-22 앰플리피카 인코포레이티드 모발 성장 촉진용 조성물 및 방법
KR102368100B1 (ko) 2020-07-20 2022-02-25 영인기술(주) 변압기용 단자 조립 어셈블리
CN112587475B (zh) * 2020-12-18 2022-09-13 华熙生物科技股份有限公司 一种载药凝胶及其制备方法
CN117304368B (zh) * 2023-11-29 2024-03-01 杭州湃肽生化科技有限公司 一种透明质酸钠与胶原五肽的组合物及其应用

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2583096A (en) * 1949-01-15 1952-01-22 Searle & Co Process for the production of high viscosity hyaluronic acid
GB769287A (en) 1954-08-18 1957-03-06 American Home Prod Preparation of partially depolymerized hyaluronic acid and therapeutic compositions thereof
GB818336A (en) 1956-06-22 1959-08-12 Erba Carlo Spa A new acid aminopolysaccharide and a process for the production thereof
US3042667A (en) * 1959-03-10 1962-07-03 Pharmacia Ab Process for producing dextran derivatives and products resulting therefrom
FR1425265A (fr) * 1962-05-14 1966-01-24 Parke Davis & Co Procédé de préparation d'un nouveau polysaccharide et de ses sels
NL123338C (es) * 1961-12-08
FR3715M (fr) * 1964-06-11 1965-11-29 Lucien Nouvel Antithermiques et antirhumatismaux améliorés.
US3357784A (en) * 1964-09-30 1967-12-12 Kendall & Co Exposure to intense ultraviolet light to improve characteristics of cellulosic fabrics in divinyl sulfone and glyoxal cross-linking processes
AT252264B (de) * 1965-03-17 1967-02-10 Etapharm Chem Pharm Lab Ges M Verfahren zur Herstellung eines reinen hochviskosen Hyaluronsäurepräparates
US3887703A (en) * 1967-03-24 1975-06-03 Oreal Mucopolysaccharides, their preparation and use in cosmetic and pharmaceutical compositions
US3792164A (en) * 1970-03-31 1974-02-12 Chemway Corp Ophthalmic composition comprising water-soluble alkaloid salts of polyuronic acids
GB1283892A (en) 1970-06-08 1972-08-02 Irwin Irville Lubowe Improvements in and relating to medicinal compositions for application to the skin and/or hair
US3845201A (en) * 1972-04-24 1974-10-29 S Loucas Solid state ophthalmic medication delivery method
US3870791A (en) * 1972-04-24 1975-03-11 Heskel M Haddad Solid state ophthalmic medication delivery method
DE2364373A1 (de) * 1973-12-22 1975-07-10 Hahn Carl Dr Gmbh Pharmazeutische und kosmetische praeparate zur aeusserlichen anwendung
US4003991A (en) * 1974-08-27 1977-01-18 National Patent Development Corporation Ophthalmic formulation
GB1515963A (en) * 1975-07-15 1978-06-28 Massachusetts Inst Technology Crosslinked collagen-mucopolysaccharide composite materials
US4280954A (en) * 1975-07-15 1981-07-28 Massachusetts Institute Of Technology Crosslinked collagen-mucopolysaccharide composite materials
US4045558A (en) * 1975-10-08 1977-08-30 Merck & Co., Inc. Pilocarpine salts
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4061722A (en) * 1976-04-26 1977-12-06 Interx Research Corporation Selected quaternary ammonium salts of pilocarpine useful in reducing intraocular pressure in warm-blooded animals
US4470975A (en) * 1977-10-21 1984-09-11 The Johns Hopkins University Method and composition for the elimination of water from an animal body
US4271143A (en) * 1978-01-25 1981-06-02 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
FR2478646A2 (fr) * 1980-03-20 1981-09-25 Choay Sa Composition mucopolysaccharidique ayant une activite regulatrice de la coagulation, medicament la contenant et procede pour l'obtenir
US4255415A (en) * 1978-11-22 1981-03-10 Schering Corporation Polyvinyl alcohol ophthalmic gel
US4240163A (en) * 1979-01-31 1980-12-23 Galin Miles A Medicament coated intraocular lens
US4272522A (en) * 1979-10-15 1981-06-09 Balazs Endre A Method for stimulating phagocytic activity and synergistic compositions therefor
US4303676A (en) 1980-03-21 1981-12-01 Balazs Endre A Hyaluronate based compositions and cosmetic formulations containing same
US4328803B1 (en) * 1980-10-20 1994-01-11 Opthalmic Systems, Inc. Opthalmological procedures
JPS57185208A (en) * 1981-05-07 1982-11-15 Shiseido Co Ltd Skin cosmetic
DE3273138D1 (en) * 1981-06-02 1986-10-16 Eupan Corp Eustatic composition for nonspecifically facilitating and amplifying the generalized homeostatic regulation and maintenance, compensation and repair in living organisms
US4684627A (en) * 1981-09-08 1987-08-04 Leveen Harry H Treatment of cancer with phlorizin and its derivatives
JPS58183611A (ja) * 1982-04-19 1983-10-26 Kanebo Ltd 多相乳化型化粧料
JPS58183938A (ja) * 1982-04-21 1983-10-27 Shiseido Co Ltd 乳化組成物
JPS5925311A (ja) * 1982-07-29 1984-02-09 Shiseido Co Ltd 化粧料
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US4517295A (en) * 1983-02-18 1985-05-14 Diagnostic, Inc. Hyaluronic acid from bacterial culture
US4478822A (en) * 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
JPS59219209A (ja) * 1983-05-28 1984-12-10 Kanebo Ltd 皮膚化粧料
AU555747B2 (en) * 1983-08-09 1986-10-09 Cilco Inc. Chondroitin sulfate and sodium hyaluronate composition
EP0138572B1 (en) * 1983-10-11 1990-07-25 FIDIA S.p.A. Hyaluronic acid fractions having pharmaceutical activity, methods for preparation thereof, and pharmaceutical compositions containing the same
US4855134A (en) * 1983-10-14 1989-08-08 Sumitomo Pharmaceuticals Company, Limited Sustained-release preparation
EP0138216B1 (en) * 1983-10-14 1993-01-07 Sumitomo Pharmaceuticals Company, Limited Sustained-release ifn preparation for parenteral administration
NO161573C (no) * 1983-11-25 1989-08-30 Miles Inc Fremgangsmaate til fremstilling av hyaluronsyre.
US4487865A (en) * 1983-12-15 1984-12-11 Biomatrix, Inc. Polymeric articles modified with hyaluronate
US4500676A (en) * 1983-12-15 1985-02-19 Biomatrix, Inc. Hyaluronate modified polymeric articles
US4716224A (en) * 1984-05-04 1987-12-29 Seikagaku Kogyo Co. Ltd. Crosslinked hyaluronic acid and its use
US4629623A (en) * 1984-06-11 1986-12-16 Biomatrix, Inc. Hyaluronate-poly (ethylene oxide) compositions and cosmetic formulations thereof
US4711780A (en) * 1984-06-11 1987-12-08 Fahim Mostafa S Composition and process for promoting epithelial regeneration
US4863907A (en) * 1984-06-29 1989-09-05 Seikagaku Kogyo Co., Ltd. Crosslinked glycosaminoglycans and their use
JPS6156114A (ja) * 1984-08-27 1986-03-20 Kanebo Ltd 皮膚老化防止用化粧料
JPS6164701A (ja) * 1984-09-06 1986-04-03 Meito Sangyo Kk カチオン化デキストラン誘導体とポリウロン酸の高分子電解質錯体及びその利用
JPS61106602A (ja) * 1984-10-31 1986-05-24 Meito Sangyo Kk カチオン性デキストラン誘導体の高分子電解質錯体及びその利用
US4636524A (en) * 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4582865A (en) * 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4784990A (en) * 1985-01-18 1988-11-15 Bio-Technology General Corporation High molecular weight sodium hyaluronate
US4713448A (en) * 1985-03-12 1987-12-15 Biomatrix, Inc. Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues
SE8501723L (sv) * 1985-04-09 1986-10-10 Pharmacia Ab Preparation att anvendas vid behandling av ledinflammation
US4725585A (en) * 1985-04-26 1988-02-16 Pharmacia Ab Method of enhancing the host defense
DE3676235D1 (de) * 1985-06-04 1991-01-31 Teijin Ltd Arzneizubereitung mit verzoegerter wirkstoffabgabe.
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
US4820732A (en) * 1985-10-04 1989-04-11 The Upjohn Company Method and compositions for reducing dysfunction in angioplasty procedures
SE449003B (sv) * 1985-10-18 1987-03-30 Pharmacia Ab Sett att in vitro avskilja spermier med egen rorelseformaga medelst penetrationsmedium i vilket ingar hyaluronsyrasalt
IN166447B (es) * 1985-11-27 1990-05-12 Ethicon Inc
EP0224987B1 (en) * 1985-11-29 1992-04-15 Biomatrix, Inc. Drug delivery systems based on hyaluronan, derivatives thereof and their salts and method of producing same
US4912093A (en) * 1986-10-01 1990-03-27 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
US4784991A (en) * 1986-03-14 1988-11-15 Bio-Technology General Corp. Heavy metal salts of hyaluronic acid and their use as antimicrobial agents
US4746504A (en) * 1986-03-14 1988-05-24 Bio-Technology General Corp. Heavy metal salts of hyaluronic acid and their use as antimicrobial agents
DE3610037A1 (de) * 1986-03-21 1987-09-24 Schering Ag Nifedipinkombinationspraeparat
EP0240098A3 (en) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo and polysaccharides for the treatment of diseases caused by retroviruses
EP0244178A3 (en) * 1986-04-28 1989-02-08 Iolab, Inc Intraocular dosage compositions and method of use
US4808576A (en) * 1986-04-28 1989-02-28 Mobay Corporation Remote administration of hyaluronic acid to mammals
US4946870A (en) * 1986-06-06 1990-08-07 Union Carbide Chemicals And Plastics Company Inc. Delivery systems for pharmaceutical or therapeutic actives
SE452469B (sv) * 1986-06-18 1987-11-30 Pharmacia Ab Material bestaende av en tverbunden karboxylgrupphaltig polysackarid och forfarande vid framstellning av detsamma
US4877619A (en) * 1986-08-25 1989-10-31 Vestar, Inc. Liposomal vesicles for intraperitoneal administration of therapeutic agents
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
IT1198449B (it) * 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
US4879282A (en) * 1987-03-17 1989-11-07 Saliba Jr Michael J Medical application for heparin and related molecules
DE3854604T2 (de) * 1987-03-19 1996-03-28 Arthropharm Pty Ltd Antientzündungsmittel und zusammensetzungen.
US4795741A (en) * 1987-05-06 1989-01-03 Biomatrix, Inc. Compositions for therapeutic percutaneous embolization and the use thereof
GB8713662D0 (en) * 1987-06-11 1987-07-15 Skandigen Ab Hyaluronic acid derivatives
US4944941A (en) * 1987-08-07 1990-07-31 Genentech, Inc. Methods and compositions for the treatment of lung conditions
US4900550A (en) * 1987-08-19 1990-02-13 Amy Allene Cosmetiques, Inc. Skin care cosmetic regime
US4937270A (en) * 1987-09-18 1990-06-26 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US4913898A (en) * 1988-04-06 1990-04-03 Altobella Hair Products Inc. Hair treatment composition and method
IT1219587B (it) * 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
CA2004740A1 (en) * 1988-12-07 1990-06-07 Cary Linsky Low molecular weight heparin, heparinoid and hexuronyl hexosaminoglycan sulfate containing adhesion prevention barrier and process
JPH04503951A (ja) * 1988-12-20 1992-07-16 ラ　ホヤ　キャンサー　リサーチ　ファウンデーション 創傷治癒に活性のあるポリペプチド―ポリマー複合体
DE3900198A1 (de) * 1989-01-05 1990-07-12 Merck Patent Gmbh Topisch anwendbare pharmazeutische zubereitung
JPH0341033A (ja) * 1989-07-07 1991-02-21 Kyowa Hakko Kogyo Co Ltd 安定なモチリン類含有製剤
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5095037B1 (en) * 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
US5092841A (en) * 1990-05-17 1992-03-03 Wayne State University Method for treating an arterial wall injured during angioplasty
US5116864A (en) * 1991-04-09 1992-05-26 Indiana University Foundation Method for preventing restenosis following reconfiguration of body vessels
US5116331A (en) * 1991-04-23 1992-05-26 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Pressure transducer and system for cryogenic environments

Also Published As

Publication number Publication date
IN182348B (es) 1999-03-27
EP0626863A1 (en) 1994-12-07
HU9303282D0 (en) 1994-03-28
PT626863E (pt) 2001-08-30
SK11193A3 (en) 1993-09-09
IN175918B (es) 1995-10-28
IN178280B (es) 1997-03-22
NZ249071A (en) 1997-01-29
AP9300491A0 (en) 1993-04-30
HU211823A9 (en) 1995-12-28
CN1084064A (zh) 1994-03-23
DE69330180D1 (de) 2001-05-31
HUT75089A (en) 1997-04-28
NO943044L (no) 1994-10-19
WO1993016732A1 (en) 1993-09-02
FI943789A0 (fi) 1994-08-17
DE69330180T2 (de) 2001-11-29
IN179130B (es) 1997-08-30
JPH07506812A (ja) 1995-07-27
NO312939B1 (no) 2002-07-22
CA2061703A1 (en) 1993-08-21
PL173211B1 (pl) 1998-02-27
CN1103219C (zh) 2003-03-19
AP475A (en) 1996-03-08
CZ290637B6 (cs) 2002-09-11
NZ299280A (en) 2000-12-22
HK1005983A1 (en) 1999-02-05
FI943789A (fi) 1994-10-03
CA2061703C (en) 2002-07-02
US6140312A (en) 2000-10-31
EP0626863B1 (en) 2001-04-25
DK0626863T3 (da) 2001-07-30
AU3488893A (en) 1993-09-13
CZ9300230A3 (cs) 2002-06-12
SG52416A1 (en) 1998-09-28
HU225967B1 (en) 2008-01-28
MD960307A (ro) 1997-10-31
RO117499B1 (ro) 2002-04-30
GR3036164T3 (en) 2001-10-31
FI113522B (fi) 2004-05-14
ES2156124T3 (es) 2001-06-16
KR950700086A (ko) 1995-01-16
IN182267B (es) 1999-02-27
NO943044D0 (no) 1994-08-17
ATE200736T1 (de) 2001-05-15
KR100315371B1 (ko) 2002-06-20

Similar Documents

Publication Publication Date Title
MX9300904A (es) Composiciones que contienen acido hialuronico
MX9300905A (es) Tratamiento de enfermedad que emplea acido hialuronico y agentes anti-inflamatorios no esteroidales
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
EP0125252A1 (de) Neue verwendung eines einzelnen vitamins oder einer kombination verschiedener vitamine
DE69731610D1 (de) Orale verabreichung wirksamer mengen von hyaluronsäure
ES2153906T3 (es) Uso de incienso para el tratamiento de la enfermedad de alzheimer.
BRPI0613824A2 (pt) composição para tratamento de lesões da pele
DK0854709T3 (da) Anvendelse af boswelliasyre og derivater deraf til hæmning af normal og forøget leukocytelastase- eller plasminaktivitet
BR9802537A (pt) Método para anestesiar um paciente humano antes de cirurgias de porte dose unitária e sistema farmacêutico para administração
DE69333387D1 (de) Pharmazeutische Zusammensetzungen enthaltend Norastemizol.
BR0014895A (pt) Formulação lìquida estável, processo para a preparação da mesma, uso da mesma, uso de polietileno glicol e sal de sódio ou potássio de um inibidor h+, k+-atpase, e, método para tratar doenças gastrointestinais
Sellera et al. Methylene blue-mediated antimicrobial photodynamic therapy: A novel strategy for digital dermatitis-associated sole ulcer in a cow–A case report
AR025030A1 (es) Utilizacion de flupirtina para aliviar los dolores en las artropatias degenerativas en perros y gatos para la preparacion de un medicamento para eltratamiento de dichas afecciones
ES2182504T3 (es) Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento.
AU2018366047B2 (en) Compositions and methods for the treatment of skin lesions
US3646215A (en) Heptadecanol for medical purposes
MC2142A1 (fr) Medicament contre la toxoplasmose
MC2203A1 (fr) Medicament contre la cryptosporidiose
ES2105643T3 (es) Uso de la 2-(4-(4-clorofenil)ciclohexil)-3-hidroxi-1,4-naftoquinona para el tratamiento del cancer.
Patel et al. Management of Non Healing Ulcer with Local Application of Yastimadhu Ghrita (Glycyrrhiza Glabra L.): A Single Case Study
WO2017146602A1 (en) Chlorine or bromine salts of cetylpyridinium for use in the treatment of cutaneous and acute porphyrias and psoriasis
RU2051676C1 (ru) Радиопротектор для слизистых оболочек рта, носа, глаз и слюнных желез
CHAPIN Oil of Cade—A Topical Application in Eczematous, Impetiginous and Some Other Cutaneous Eruptions: Read before the Middlesex East Medical Society, March 16th, 1859, and Communicated for the Boston Medical and Surgical Journal
Nater Drugs used on the skin
GT199100015A (es) Metodo para administracion percutanea de ibuprofeno usando un gel hidroalcoholico